Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes. / Nielsen, Lotte B; Ploug, Kenneth B; Swift, Peter; Ørskov, Cathrine; Jansen-Olesen, Inger; Chiarelli, Francesco; Holst, Jens Juul; Hougaard, Philip; Pörksen, Sven; Holl, Reinhard; de Beaufort, Carine; Gammeltoft, Steen; Rorsman, Patrik; Mortensen, Henrik B; Hansen, Lars.
I: European Journal of Endocrinology. Supplement, Bind 156, Nr. 6, 06.2007, s. 663-71.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Co-localisation of the Kir6.2/SUR1 channel complex with glucagon-like peptide-1 and glucose-dependent insulinotrophic polypeptide expression in human ileal cells and implications for glycaemic control in new onset type 1 diabetes
AU - Nielsen, Lotte B
AU - Ploug, Kenneth B
AU - Swift, Peter
AU - Ørskov, Cathrine
AU - Jansen-Olesen, Inger
AU - Chiarelli, Francesco
AU - Holst, Jens Juul
AU - Hougaard, Philip
AU - Pörksen, Sven
AU - Holl, Reinhard
AU - de Beaufort, Carine
AU - Gammeltoft, Steen
AU - Rorsman, Patrik
AU - Mortensen, Henrik B
AU - Hansen, Lars
PY - 2007/6
Y1 - 2007/6
N2 - OBJECTIVE: The ATP-dependent K+-channel (K(ATP)) is critical for glucose sensing and normal glucagon and insulin secretion from pancreatic endocrine alpha- and beta-cells. Gastrointestinal endocrine L- and K-cells are also glucose-sensing cells secreting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotrophic polypeptide (GIP) respectively. The aims of this study were to 1) investigate the expression and co-localisation of the K(ATP) channel subunits, Kir6.2 and SUR1, in human L- and K-cells and 2) investigate if a common hyperactive variant of the Kir6.2 subunit, Glu23Lys, exerts a functional impact on glucose-sensing tissues in vivo that may affect the overall glycaemic control in children with new-onset type 1 diabetes.DESIGN AND METHODS: Western blot and immunohistochemical analyses were performed for expression and co-localisation studies. Meal-stimulated C-peptide test was carried out in 257 children at 1, 6 and 12 months after diagnosis. Genotyping for the Glu23Lys variant was by PCR-restriction fragment length polymorphism.RESULTS: Kir6.2 and SUR1 co-localise with GLP-1 in L-cells and with GIP in K-cells in human ileum tissue. Children with type 1 diabetes carrying the hyperactive Glu23Lys variant had higher HbA1C at diagnosis (coefficient = 0.61%, P = 0.02) and 1 month after initial insulin therapy (coefficient = 0.30%, P = 0.05), but later disappeared. However, when adjusting HbA1C for the given dose of exogenous insulin, the dose-adjusted HbA1C remained higher throughout the 12 month study period (coefficient = 0.42%, P = 0.03).CONCLUSIONS: Kir6.2 and SUR1 co-localise in the gastrointestinal endocrine L- and K-cells. The hyperactive Glu23Lys variant of the K(ATP) channel subunit Kir6.2 may cause defective glucose sensing in several tissues and impaired glycaemic control in children with type 1 diabetes.
AB - OBJECTIVE: The ATP-dependent K+-channel (K(ATP)) is critical for glucose sensing and normal glucagon and insulin secretion from pancreatic endocrine alpha- and beta-cells. Gastrointestinal endocrine L- and K-cells are also glucose-sensing cells secreting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotrophic polypeptide (GIP) respectively. The aims of this study were to 1) investigate the expression and co-localisation of the K(ATP) channel subunits, Kir6.2 and SUR1, in human L- and K-cells and 2) investigate if a common hyperactive variant of the Kir6.2 subunit, Glu23Lys, exerts a functional impact on glucose-sensing tissues in vivo that may affect the overall glycaemic control in children with new-onset type 1 diabetes.DESIGN AND METHODS: Western blot and immunohistochemical analyses were performed for expression and co-localisation studies. Meal-stimulated C-peptide test was carried out in 257 children at 1, 6 and 12 months after diagnosis. Genotyping for the Glu23Lys variant was by PCR-restriction fragment length polymorphism.RESULTS: Kir6.2 and SUR1 co-localise with GLP-1 in L-cells and with GIP in K-cells in human ileum tissue. Children with type 1 diabetes carrying the hyperactive Glu23Lys variant had higher HbA1C at diagnosis (coefficient = 0.61%, P = 0.02) and 1 month after initial insulin therapy (coefficient = 0.30%, P = 0.05), but later disappeared. However, when adjusting HbA1C for the given dose of exogenous insulin, the dose-adjusted HbA1C remained higher throughout the 12 month study period (coefficient = 0.42%, P = 0.03).CONCLUSIONS: Kir6.2 and SUR1 co-localise in the gastrointestinal endocrine L- and K-cells. The hyperactive Glu23Lys variant of the K(ATP) channel subunit Kir6.2 may cause defective glucose sensing in several tissues and impaired glycaemic control in children with type 1 diabetes.
KW - ATP-Binding Cassette Transporters
KW - Adolescent
KW - Blotting, Western
KW - C-Peptide
KW - Child
KW - Diabetes Mellitus, Type 1
KW - Eating
KW - Female
KW - Gastric Inhibitory Polypeptide
KW - Genotype
KW - Glucagon
KW - Glucagon-Like Peptide 1
KW - Hemoglobin A, Glycosylated
KW - Humans
KW - Hyperglycemia
KW - Hypoglycemic Agents
KW - Ileum
KW - Immunohistochemistry
KW - Insulin
KW - Islets of Langerhans
KW - Male
KW - Polymorphism, Restriction Fragment Length
KW - Potassium Channels
KW - Potassium Channels, Inwardly Rectifying
KW - Receptors, Drug
KW - Sulfonylurea Receptors
U2 - 10.1530/EJE-06-0756
DO - 10.1530/EJE-06-0756
M3 - Journal article
C2 - 17535866
VL - 156
SP - 663
EP - 671
JO - Acta Endocrinologica, Supplement
JF - Acta Endocrinologica, Supplement
SN - 0804-4635
IS - 6
ER -
ID: 132050087